The stock of Boston Scientific Corp (NYSE:BSX) last traded at $105.77, down -0.20% from the previous session.
BSX stock price is now 10.71% away from the 50-day moving average and 26.06% away from the 200-day moving average. The market capitalization of the company currently stands at $155.89B.
With the price target maintained at $108, Deutsche Bank recently Upgraded its rating from Hold to Buy for Boston Scientific Corp (NYSE: BSX). , while ‘Goldman’ rates the stock as ‘Buy’
In other news, LUDWIG EDWARD J, Director sold 12,000 shares of the company’s stock on Feb 11 ’25. The stock was sold for $1,265,815 at an average price of $105.48. Upon completion of the transaction, the Director now directly owns 24,398 shares in the company, valued at $2.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 12 ’25, Officer DANIEL BRENNAN bought 15,087 shares of the business’s stock. A total of $1,585,135 was incurred on buying the stock at an average price of $105.07. A total of 0.46% of the company’s stock is owned by insiders.
During the past 12 months, Boston Scientific Corp has had a low of $64.54 and a high of $107.17. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 1.48, and a quick ratio of 1.02. According to the stock market information, the enterprise value for the company is $161604091904, which is based on a 84.77 price-to-earnings ratio, a 6.29 price-to-earnings-growth ratio, and a beta of 0.78. The fifty day moving average price for BSX is $95.24 and a two-hundred day moving average price translates $83.74485 for the stock.
The latest earnings results from Boston Scientific Corp (NYSE: BSX) was released for 2024-09-30. The net profit margin was 11.07% and return on equity was 9.05% for BSX. The company reported revenue of $4.21 billion for the quarter, compared to $3.53 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 19.34 percent.
